Co-founder of Gero (Singapore), being responsible for business development and legal affairs. Gero is an AI driven drug discovery company using big human medical data for identification of innovative therapeutics. Gero’s flagship project is a pipeline pipeline of longevity therapeutics. Recent results include experimental therapies rejuvenating / reducing biological age and frailty in mice.

Gero investors are serial pharma and IT entrepreneurs (previous exits to Google, Facebook).

Gero works with leading academic partners, including Brian Kennedy, Aubrey de Grey, Robert J. Shmookler Reis, Vadim Gladyshev, Yuri Aulchenko, Andrei Gudkov and others to translate aging biology into life-changing interventions against biological aging acceleration in cancer, metabolic disorders and immunosenescence.